

# KEYWORD INDEX

- ABT-199: 37, 108, 109, 147, 261  
ABVD: 8, 41, 82, 118, 171, 253, 325, 326, 328, 464  
activated B-cell-like (ABC): 25, 49, 50, 136, 158, 214  
AKT: 397  
ALK: 240, 241  
allogeneic stem cell transplant (alloSCT): 30, 33, 34, 56, 68, 180, 247, 330, 333, 349, 395, 468  
anaplastic large cell lymphoma (ALCL): 68, 73, 84, 100, 181, 239, 240, 241, 315, 329, 435, 916, 917  
angiimmunoblastic T-cell lymphoma (AITL): 40, 72, 84, 101, 112  
anthracycline: 216, 377, 445, 447  
antibody-dependent cytotoxicity (ADC): 275, 276  
apoptosis: 152, 265, 269, 275, 471  
Ara-C: 59, 352, 373, 386  
Array-comparative genomic hybridization: 21, 26, 72, 316  
aurora kinase: 279  
autologous stem cell transplantation (ASCT): 9, 29, 30, 31, 62, 68, 74, 102, 119, 120, 180, 200, 209, 247, 303, 331, 333, 345, 349, 351, 373, 386, 388, 389, 390, 392, 393, 394, 432, 437, 443  
B-cell lymphoma: 2, 17, 18, 22, 23, 27, 38, 39, 55, 79, 91, 96, 107, 116, 139, 142, 149, 155, 156, 158, 186, 280, 281, 286, 287, 290, 302, 304, 313, 338, 347, 368, 369, 376, 388, 398, 405, 447, 449, 469, 474, 477, 478, 479, 481, 904, 908, 912  
B-cell receptor (BCR): 22, 38, 39, 51, 94, 105, 153, 165, 264  
B-cells: 183  
BCL2: 161, 162, 261, 307, 308, 309, 311, 362, 422, 476  
BCL6: 162, 225, 362  
BEACOPP: 8, 118  
BEAM: 29, 388  
bendamustine: 13, 15, 56, 59, 60, 62, 90, 123, 178, 198, 249, 341, 390, 452  
bleomycin: 41  
bortezomib: 57, 109, 202, 438, 440, 911  
brentuximab vedotin: 87, 88, 89, 90, 91, 92, 120, 177, 178, 306, 329, 330, 333, 435, 436, 916, 917, 918  
bromodomains: 36, 270, 271, 272  
BTK: 472, 481, 906  
Burkitt lymphoma (BL): 21, 46, 51, 66, 67, 114, 116, 222, 289, 479  
carboplatin: 373  
CD19: 139, 140, 285, 312  
CD20: 105, 123, 201, 275  
CD22: 381  
CD3: 285  
CD30: 91, 92, 120, 177, 181, 329, 330, 916, 917  
CD37: 141, 274, 286, 287  
CD5: 312, 313  
chemokines: 281, 405, 452  
Chemotherapy: 31, 46, 67, 89, 103, 125, 179, 218, 228, 234, 236, 243, 245, 248, 251, 260, 273, 313, 351, 352, 371, 376, 414, 432, 433, 446, 448, 469  
chromosomal translocations: 26, 37, 146  
chronic lymphocytic leukemia (CLL): 13, 38, 42, 45, 53, 54, 55, 56, 95, 98, 105, 106, 141, 169, 170, 182, 183, 184, 185, 263, 284, 288, 313, 314, 456, 903, 906, 914, 915, 919, 922  
classical Hodgkin lymphoma (cHL): 10, 23, 28, 118, 176, 181, 295, 309, 316, 320, 328, 464, 465, 469, 475, 478, 922  
CNS prophylaxis: 220, 221, 368, 422  
cutaneous anaplastic large cell lymphoma (cALCL): 73  
cutaneous B-cell lymphoma (CBCL): 412, 413  
cutaneous T-cell lymphoma (CTCL): 40, 276, 277, 298, 434, 436  
cyclins: 26, 57  
cyclophosphamide: 450  
cytogenetics: 37, 55, 109, 239, 290  
cytokines: 167, 201, 281, 915  
DA-R-EPOCH: 393  
Deauville's criteria: 81, 258, 355, 464, 466  
deep sequencing: 19, 20, 112, 133, 155, 163, 165, 316, 399  
dendritic cells: 480, 912  
dexamethasone (DXM): 471  
DHAP: 283, 374, 911  
diffuse large B-cell lymphoma (DLBCL): 15, 19, 21, 28, 35, 36, 39, 46, 48, 49, 50, 78, 79, 80, 83, 86, 91, 92, 93, 97, 106, 115, 126, 127, 128, 129, 130, 131, 133, 136, 140, 144, 145, 146, 147, 152, 153, 155, 156, 157, 158, 159, 160, 161, 163, 164, 200, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 223, 224, 226, 228, 229, 252, 257, 258, 260, 262, 265, 267, 268, 269, 270, 271, 274, 282, 283, 284, 285, 295, 299, 300, 302, 303, 305, 306, 307, 311, 317, 318, 345, 356, 357, 358, 359, 361, 362, 363, 364, 366, 367, 371, 372, 373, 374, 375, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 397, 403, 418, 419, 455, 458, 460, 462, 466, 467, 476, 481, 482, 483, 905, 908, 911, 913  
DNA microarrays: 163, 164, 289  
doxorubicin: 87, 251, 445, 446, 448  
“double-hit” lymphomas: 110, 115, 146, 161, 162, 304  
EBER: 367  
elderly: 60, 89, 134, 185, 203, 216, 217, 231, 232, 300, 377, 380, 382, 384, 394, 403, 404, 441, 913  
epigenetics: 36, 144, 145, 170, 271, 272, 305  
Epstein-Barr virus (EBV): 95, 97, 299, 300, 301, 367, 396, 427, 438, 921  
ERK: 186, 471  
ESHAP: 385  
etiology principles: 50  
etoposide: 99  
extranodal lymphomas: 75, 102, 103, 210, 219, 228, 229, 234, 238, 244, 245, 315, 318, 378, 402, 403, 417, 418, 420, 421, 424, 427, 428, 429, 470, 920, 921  
extranodal marginal zone lymphoma of MALT type: 124, 230  
EZH2: 145  
F-18-fluorodeoxyglucose (FDG): 8, 254, 461, 465, 469, 470  
flow cytometry: 150, 151, 237, 296, 312, 437  
fludarabine: 340  
fluorescence in situ hybridization (FISH): 18, 239  
follicular lymphoma (FL): 11, 22, 24, 25, 29, 30, 52, 121, 122, 142, 145, 147, 148, 150, 151, 187, 188, 189, 190, 191, 192, 193, 195, 196, 197, 256, 267, 284, 293, 294, 316, 335, 336, 338, 339, 340, 341, 345, 346, 348, 349, 376, 457, 458, 480, 904, 907, 910, 912  
fostamatinib: 265  
GCB lymphoma subtype: 25, 157, 300  
gemcitabine: 246, 381, 387, 425  
gene expression profile (GEP): 25, 35, 93, 112, 114, 115, 127, 214, 266, 278, 291, 477  
gene rearrangement: 18, 19, 292  
germinal center (GC): 17  
germinal center B cell-like (GCB): 49, 158, 214, 221, 257  
Helicobacter pylori: 411  
hepatitis B: 96, 98, 366, 454, 455  
hepatitis C: 343, 366, 379, 409  
hepatosplenic T-cell lymphoma: 71  
high-dose steroids: 444  
high-dose therapy (HDT): 157, 247, 386, 450  
highly active anti-retroviral therapy (HAART): 325, 370  
histone deacetylase inhibitors: 16, 80, 104, 224, 279, 477  
Hodgkin lymphoma (HL): 8, 41, 43, 44, 46, 82, 87, 88, 89, 90, 94, 107, 119, 120, 126, 171, 172, 173, 174, 175, 177, 178, 179, 180, 253, 254, 255, 259, 266, 278, 297, 301, 302, 320, 321, 322, 323, 325, 326, 327, 329, 330, 331, 332, 333, 334, 387, 456, 459, 463, 482, 916  
human herpes virus (HHV): 201  
human immunodeficiency virus (HIV): 201, 218, 302, 310, 325, 369, 370  
human T-lymphotropic virus (HTLV): 113  
hyper-CVAD: 62  
ibrutinomab tiuxetan: 340, 384  
ibrutinib: 55, 77, 78, 105, 106, 108, 136, 165, 207, 208, 261, 273, 344, 477, 906, 909  
ICE: 380, 415  
Idelalisib (CAL-101, GS-1101): 42, 45, 193, 194, 273, 280, 473  
immune system: 24, 127, 240, 480  
immunotherapy: 10, 130, 188, 191, 195, 197, 200, 220, 222, 356, 357, 480, 912, 914  
Immunoconjugates: 274  
immunodeficiency-associated lymphomas: 369, 918  
immunoglobulins (Ig): 155, 292  
immunohistochemistry (IHC): 24, 115, 148, 294, 297, 306, 308, 311, 439

- immunomodulators (IMiDs): 16, 137, 206, 342, 354, 439
- immunophenotype: 149, 150, 238, 305, 307, 426
- immunosuppression: 97, 295, 396, 918
- immunotoxins: 381
- indolent lymphoma: 123, 142, 186, 192, 237, 287, 342, 343, 401, 409, 904, 907, 920
- induction treatment: 70, 103, 231, 232, 372, 903
- interleukines: 915
- JAK/STAT: 36, 79, 107, 156, 237
- Ki-67: 58, 408, 909
- L-asparaginase: 75, 248, 425, 430
- lenalidomide: 5, 11, 12, 13, 14, 15, 16, 60, 78, 101, 137, 191, 205, 206, 209, 273, 354, 374, 385, 442, 905, 910
- lomustine: 331
- lymphoblastic lymphoma (LBL): 65, 69, 471
- lymphoplasmacytic lymphoma (LPL): 125
- macrophages: 137, 358
- magnetic resonance imaging (MRI): 85
- MALT1: 124
- mantle cell lymphoma (MCL): 2, 14, 26, 57, 58, 59, 60, 61, 62, 165, 166, 167, 168, 202, 203, 204, 205, 206, 207, 208, 209, 261, 272, 290, 312, 350, 351, 352, 353, 354, 355, 472, 909
- marginal zone lymphoma (MZL): 12, 198, 230, 337, 408, 410, 411, 910
- methotrexate (MTX): 75, 221, 226, 248, 372, 404
- microRNA: 22, 153, 271
- minimal residual disease (MRD): 59, 204, 437
- molecular genetics: 17, 18, 20, 51, 114, 144, 260, 288, 289, 292, 483, 908
- monoclonal antibodies (MoAb): 29, 40, 140, 141, 286
- monoclonal gammopathy of undetermined significance (MGUS): 5
- mouse models: 51, 113, 144, 260, 264
- mTOR inhibitors: 250, 282, 472
- Mucosa-Associated Lymphoid Tissue (MALT): 401, 418, 920
- multiple myeloma (MM): 5, 10, 37, 80, 109, 168, 319, 438, 439, 440, 441, 442, 443, 458, 922
- MYC: 110, 114, 116, 157, 159, 161, 162, 262, 289, 303, 308, 311, 473
- mycosis fungoides (MF): 436
- MYD88: 77, 108, 125, 132, 159, 160, 270, 908
- NF- $\kappa$ B: 262, 268, 270, 475
- nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): 94, 324
- non-Hodgkin lymphoma (NHL): 10, 17, 20, 27, 45, 65, 69, 75, 102, 106, 121, 129, 142, 147, 148, 149, 154, 174, 193, 199, 242, 264, 266, 269, 275, 286, 298, 310, 319, 327, 331, 332, 347, 350, 359, 360, 365, 370, 387, 390, 391, 394, 395, 400, 402, 405, 419, 421, 427, 428, 431, 445, 451, 453, 456, 461, 470, 481, 904, 910, 921, 922
- obinutuzumab: 123, 906, 914, 915
- ofatumumab: 198, 199, 920
- P53: 116, 168, 288, 290
- PAX5: 269
- performance status: 359
- peripheral T-cell lymphomas (PTCL): 33, 70, 72, 74, 84, 100, 231, 232, 233, 235, 246, 247, 249, 399, 425, 426, 430, 433, 435, 437
- PI3K/AKT/mTOR: 35, 38, 42, 45, 57, 78, 79, 80, 107, 110, 193, 263, 266, 267, 268, 280, 281, 284, 397, 442, 473, 907
- positron emission tomography (PET): 81, 82, 83, 84, 118, 119, 173, 175, 204, 210, 215, 223, 252, 255, 256, 257, 258, 326, 355, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 901
- post-transplant lymphoproliferative disorders (PTLDs): 179, 396, 407, 423
- pralatrexate: 104
- primary CNS lymphoma (PCNSL): 9, 85, 133, 134, 135, 136, 137, 225, 227, 403, 404, 405, 406, 483
- primary mediastinal large B-cell lymphoma (PMLBCL): 28, 48, 49, 81, 156, 327, 414, 415, 416, 901
- prognostic indices: 24, 54, 70, 74, 81, 95, 99, 124, 126, 127, 130, 170, 179, 188, 210, 213, 233, 240, 314, 319, 346, 356, 357, 358, 363, 364, 367, 408, 426, 430, 465
- proteasome: 278, 442, 473
- PTEN: 267
- PTLD: 21, 918
- R-ACVBP: 215
- R-CHOP: 92, 128, 202, 215, 217, 218, 258, 282, 307, 357, 359, 360, 364, 366, 372, 382, 383, 413, 415, 448, 905
- R-FC: 185
- radioimmunotherapy (RIT): 128, 204, 287, 340, 341, 384
- reduced-intensity conditioning regimen (RIC): 349
- Reed-Sternberg cells: 475
- rituximab: 9, 11, 12, 15, 122, 126, 130, 183, 184, 187, 191, 195, 196, 197, 199, 213, 222, 223, 226, 252, 274, 283, 304, 345, 346, 347, 348, 351, 363, 383, 385, 393, 396, 398, 449, 905, 909
- romidepsin (RD): 16, 246, 279, 434, 902
- salvage treatment: 14, 119, 178, 180, 224, 246, 334, 374, 375, 387, 400, 410, 911
- Sezary syndrome: 40, 276, 436
- SNP: 292
- splenectomy: 409
- splenic marginal zone lymphoma (SMZL): 272, 409
- subcutaneous panniculitis-like T-cell lymphoma (SPTL): 236
- SYK: 39, 42, 265
- T-cell lymphoma (TCL): 23, 31, 32, 71, 99, 104, 113, 235, 236, 238, 242, 243, 244, 248, 250, 278, 279, 369, 429, 431, 432, 458, 902
- T-cell receptor (TCR): 112, 181
- T-cells: 139, 149, 150, 151, 285, 921
- temozolomide: 228
- temsirolimus: 229, 283
- testicular lymphoma: 159, 422
- thiotepa: 9
- TRAIL: 167
- VEGFR: 167
- vinblastine: 68, 87
- Vinca alkaloids: 217
- Waldenström's macroglobulinemia (WM): 77, 108, 125, 194, 199, 200, 291, 344
- Waldeyer ring: 419
- zevalin: 457